Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
"It helps to underline another significant benefit of this class of medication," Dr
Gradual increase in physical activity that feels sustainable
Increases energy levels
In both cases, the goal is to restore adequate carnitine levels and address any underlying contributing cause
Despite the impressive results achieved, weight reduction is still considerably lower than bariatric surgery leaving important unmet medical needs and opportunities for obesity treatments
US$ 28.41
US$ 26.16
US$ 22.95
US$ 29.09
US$ 21.94
US$ 27.94
